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Abstract
Background: Vav1 and RasGRF2 are GDP/GTP exchange factors for Ras superfamily GTPases with roles in the development
and/or effector functions of T–lymphocytes.
Methodology/Principal Findings: Given that the phenotype of Vav1–/–, Rasgrf2–/– and Vav1–/–;Rasgrf2–/– mice has been
studied so far in young animals, we decided to explore the long–term consequences of the inactivation of those loci in the
immune system. Unexpectedly, our studies revealed that the inactivation of the Vav1 proto–oncogene favors the formation
of lymphoblastic lymphoma–like tumors in aging mice. Those tumors, that can be found either localized exclusively inside
the thymus or widely disseminated in hematopoietic and non–hematopoietic tissues, are composed of CD3+ lymphoblasts
that display heterogeneous combinations of CD4 and CD8 surface markers. Interestingly, the additional deletion of the
Rasgrf2 gene induces a shortening in the latency period for the development of those tumors, an increase in the percentage
of disseminated tumors outside the thymus and, as a result, higher mortality rates.
Conclusions/Significance: These data reveal unexpected negative roles for Vav1 and RasGRF2 in different stages of T–cell
lymphoma progression. They also suggest that the inactivation of Vav1 function may represent an inadequate strategy to
treat T–cell lymphomas, especially those associated with low levels of Rasgrf2 gene expression.
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Introduction
Ras and Rho/Rac proteins play essential roles in normal signal
transduction and pathological states, since they activate intracellular
pathways that impinge directly in biological processes related to cell
proliferation, survival and motility [1-6]. Under normal conditions,
these proteins cycle between an inactive, GDP–bound state and an
active, GTP–bound conformation. The cycling between these two
conformations is regulated by GDP/GTP exchange factors (GEFs),
GTPase activating proteins (GAPs) and, in some cases, by Rho
GDP dissociation inhibitors (RhoGDIs). GEFs promote the rapid
exchange of GDP by GTP during cell signaling, thereby helping the
rapid transition of Ras and Rho/Rac GTPases from the inactive to
active states [7]. GAP proteins enhance the hydrolysis rates of
bound GTP molecules, thus favoring the inactivation of Ras and
Rho/Rac GTPases at the end of the stimulation cycle [7]. Finally,
RhoGDIs contribute to the downmodulation of Rho/Rac–
dependent GTPase pathways by retrieving the GTPases from
membranes and, subsequently, by maintaining them sequestered in
the cytosol in their inactive, GDP–bound conformation [8-10]. The
importance of this regulatory cycle is underscored by the
observation that point mutations affecting either GTP hydrolysis
or the intrinsic GDP/GTP exchange of Ras and Rho/Rac proteins
lead to the generation of GTPases with high (in the case of Ras
GTPases) or intermediate (in the case of Rho/Rac proteins)
oncogenic potential [1,5,6].
Whereas it has been always assumed that tumorigenic processes
could be positively and negatively regulated by GEFs and GAPs/
RhoGDIs, respectively, recent data have revealed that this
regulatory picture is more complex than initially anticipated. For
example, it has been recently shown that RhoGDIs are required for
the efficient transforming activity of the GTPase Cdc42, an
observation that suggest that these GTPase inhibitors may also
play positive roles in the translocation and/or effector phase of these
GTPases [11]. On the other hand, recent observations have shown
that RASGRF2, a human gene encoding a dual GEF with specificity
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for Ras and Rho/Rac proteins, is either hypermethylated or
downregulated transcriptionally in cancer cell lines and primary
tumors [12-15], a biological property reminiscent of genes
associated with tumor suppressor activities. Consistent with this
possibility, it has been recently demonstrated that the overexpres-
sion of RasGRF2 affects negatively the transforming properties of a
colon cancer cell line [15]. Despite the above results, there is no
actual evidence indicating that this GEF could play tumor
suppressor–like activities in tumorigenic processes in vivo. Likewise,
we have no information regarding the implication of other GEFs in
the negative regulation of tumor growth. In fact, the overexpression
of wild type or the expression of constitutively–active mutant
versions of many GEFs have been usually associated to oncogenesis
rather than to growth inhibitory signals. For example, the
transforming activity of the human VAV1 and the RASGRP1
oncogenes, two loci encoding GEFs for either Rho/Rac (VAV1) or
Ras (RASGRP1), was the biological read–out that allowed the
discovery of these important regulatory proteins [16,17].
Recently, we described that the Vav1 and RasGRF2 GEFs play
synergistic roles in the activation of specific T–cell receptor (TCR)
downstream signaling pathways, including the optimal activation
of phospholipase C–c, the stimulation of the nuclear factor of
activated T–cells, and the transcriptional upregulation of cytokine
genes [18]. Consistent with this signaling cross–talk, we demon-
strated that the deletion of the mouse Rasgrf2 gene aggravated the
defective proliferative responses of mature, TCR–stimulated
Vav1–/– T–cells [18]. Given the aforementioned defects, we
decided to perform long–term studies with Vav1–/–, Rasgrf2–/–,
Vav1–/–;Rasgrf2–/– and control animals to investigate the possible
development of additional, age–dependent immune defects such as
autoimmune disease. Unexpectedly, we found that the loss of Vav1
and Rasgrf2 genes cooperated synergistically in the development of
very aggressive T–cell lymphomas in mice. These observations
indicate that in some specific signaling contexts, the absence of
GEF function may contribute to, rather than impacting negatively
on, tumorigenesis. They also suggest that anti–cancer therapies
directed against GEFs may not be advisable in some tumor types.
Results
Synergistic Effect of Vav1 and Rasgrf2 Gene Deficiencies
in Leukemia/Lymphoma Development
Given the defects observed in Vav1–/–, Rasgrf2–/– and
Vav1–/–;Rasgrf2–/– mice in TCR–mediated responses, we decided
to perform long–term studies with those animals to investigate the
possible development of additional, age–dependent immune
defects. To avoid interferences with genetic polymorphisms, all
mouse strains were previously homogenized in the B10.BR
genetic background. We observed that whereas wild type (6%,
n=32) and Rasgrf2–/– (12%, n= 24) animals showed a low
disease/death rate up to a year of age, Vav1–/– animals (32%,
n=25) and, to a larger extent, the double Vav1–/–;Rasgrf2–/– mice
(68.6%, n=42) were prone to either dying prematurely or falling
sick as they aged (Figure 1A). The latency periods for disease
development were also shorter in Vav1–/–;Rasgrf2–/– mice than in
the rest of genotypes (Figure 1A). Unexpectedly, the examination
of dead and euthanized sick animals indicated that the disease/
death cause was the presence of highly disseminated lymphoid
tumors rather than any type of autoimmune disease. Specifically,
we observed hyperplasia of thymi, massive splenomegalies and
lymphadenopathies in most of the animals analyzed (Figure 1B).
The above tissues also showed a disruption of their normal
histological structures as a consequence of the extensive growth
and/or colonization of the whole tissue by tumor cells. Due to
this, the typical separation of cortical and medullar areas, the
white and red pulp areas, and the germinal/peripheral centers
where completely blurred or eliminated in the thymi, spleen and
mesenteric lymph nodes, respectively (Figure 1C, compare
upper and lower panels). We also detected extensive infiltrations
of tumor cells in kidneys (Figure 1C), lungs (Figure 1C), liver
(Figure 1C), intestine (data not shown), and bone marrow (see
below). Interestingly, we did not find increased rates of leukemia/
lymphoma in aging Vav2–/–, Vav3–/– or Vav2–/–;Vav3–/– mice
when compared to control littermates (n.30 for each genotype,
data not shown). These results indicated that the Vav1 proto–
oncogene deficiency in mice leads in the long–term to leukemia/
lymphoma and that the loss of the Rasgrf2 gene further
accentuates the progression of that disease.
Characterization of Tumors Present in Vav1–/–;Rasgrf2–/–
Mice
Flow cytometry analysis of cells obtained from the thymus, spleen
and bone marrow of tumor–bearing Vav1–/–;Rasgrf2–/– and Vav1–/–
animals revealed the presence of a new population characterized by
the surface expression of CD3, a T–cell specific marker (Figure 2A).
The percentage of cells belonging to this population was highly
variable among the animals under study (12–90%, see an example
by comparing the left panels of Figure 2A). Consistent with these
cytometry data, immunohistochemical analysis of tissue sections
indicated that the tumor cells present in both hematopoietic and
non–hematopoietic tissues displayed high levels of CD3 expression
(Figure 2B). By contrast, these tumor cells were more heteroge-
neous in terms of the surface expression of the CD4 and CD8
markers. Thus, we found cases in which tumor cells were
homogeneously double positive for those markers (Figure 2C,
animal #1), cases in which the leukemia/lymphomas were
composed of two separate CD4+CD8+ and CD8+ populations
(Figure 2C, animal#2), and cases in which single CD8+ cells were
observed in the tumor cell population (Figure 2C, animal #3).
Although the distributions of the CD4 and CD8 markers were
rather stochastic in the tumor cells analyzed, we did find that single
positive T–cells were usually skewed towards the CD8+ rather than
to the CD4+ lineage. Despite this variability among animals, the
surface immunophenotype of the leukemia/lymphoma cells from
the same animal was similar independently of the tissue source they
were obtained from (Figure 2C).
We next investigated the proliferative status of the leukemia/
lymphoma cells present in these animals. Flow cytometry analyses
indicated that tumor cells contained large percentages of blasts, an
indication of high proliferative rates (Figure 2D). Immunohisto-
chemistry experiments confirmed these results, since all tumors
sections analyzed displayed higher expression levels of the
proliferating cell nuclear antigen (PCNA), a processivity factor
for DNA polymerase d whose expression correlates with active cell
proliferation (Figure 2B) [19]. Despite this, we could not observe
any increase in the expression of the surface marker CD69 in
thymic, splenic, or bone–marrow derived leukemia/lymphoma
cells by flow cytometry (data not shown). Since CD69 is
upregulated in proliferating T–cells in a TCR–dependent manner
[20], these results suggest that the proliferation of those leukemia/
lymphoma cells occurs independently of TCR engagement.
Similar data were obtained with tumors derived from single
Vav1–/–, Rasgrf2–/– and wild type animals.
Thymic Origin of Tumors
In order to investigate the origin and ontology of those tumor
cells, we decided to study the T–cell compartment in tumor–free
animals. To this end, we performed histological and flow
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cytometry analyses of wild type, Vav1–/–, Rasgrf2–/– and
Vav1–/–;Rasgrf2–/– animals that were six– to eight–week–old, an
age period in which we had not detected any deaths or sickness
sign in the animals. In addition, we focused our attention on mice
that had survived up to a year of age and that, therefore, were
categorized as ‘‘disease–free’’ animals in our first screening
phase. In the case of young mice, we observed no obvious
tumoral or pre–neoplasic manifestations in any of the animals
analyzed (n= 20). Moreover, we found that wild type and
Rasgrf2–/– mice exhibited the expected distribution of thymocyte
subpopulations (Figure 3A) and of splenic CD3+, CD4+ and
CD8+ T–cells (Figure 3B). As expected [21], Vav1–/– mice did
show alterations in the percentage of thymocyte subpopulations
due to a defective transition of CD4–CD8– cells from the
CD44–CD25+ to the CD44–CD25– stage (Figure 3A). Although
the relative percentages of CD4+CD8+ thymocytes did not
change when compared with wild type counterparts and
Rasgrf2–/– mice (Figure 3A), we did observe a reduction in the
total numbers of production of these cells that resulted in lower
levels of thymic cellularity (data not shown). This defect has been
previously attributed to a defective positive selection that leads to
enhanced mortality rates in this thymic subpopulation [21]. As
previously reported [21,22], Vav1–/– mice also manifested T–
lymphopenia as inferred by the increased in the percentage of
B220+ B–cells in the spleen (Figure 3B). The combined
inactivation of the Rasgrf2 and Vav1 loci did not aggravate the
thymocyte developmental/selection defects or the T–cell lym-
phopenia induced by the single Vav1 gene deficiency (Figure 3).
Hence, these results indicate that young animals do not have
neoplasic or pre–neoplasic manifestations and that the inactiva-
tion of the Rasgrf2 gene does not accentuate the already severe
immune defects caused by the Vav1–deficiency.
In contrast to the results with young animals, we observed that
one–year–old, ‘‘tumor–free’’ animals displayed a high frequency of
hyperplasic thymi with disrupted compartmentalization in cortical
and medullary regions (Figure 4A; data not shown). As in the case
of leukemia/lymphoma cells from the aforementioned tumor–
bearing animals, these thymocytes expressed excess amounts of
CD3+ (Figure 4A,B), were PCNA positive (Figure 4A), and
showed a heterogeneous display of CD4 and CD8 surface molecules
(Figure 4C and data not shown). However, we could not find any
infiltration of CD3+ lymphoma cells in other tissues (Figure 4A,C).
Furthermore, no signs of splenomegalia or lymphadenopathy could
be detected in these ‘‘tumor–free’’ animals (data not shown).
Kidneys, lungs and livers were also normal in these mice
(Figure 4A). These thymic alterations were detected at very high
rates in animals of both Vav1–/– (<85%, n=14) and Vav1–/–;-
Rasgrf2–/– (<80%, n=14) genotypes (Figure 4D). These results
indicate that the T–cell leukemia/lymphomas found in these
animals are of thymic origin. As in the case of invasive/metastatic
Figure 1. The combined Vav1/Rasgrf2 gene deficiency enhances the rates of lymphomas. (A) Kaplan–Meyer distribution graph showing
the percentage of survival rates of mice of the indicated genotypes. NS, non–statistically significant values; *, P,0.01; **, P,0.05. (B) Examples of
non–tumorigenic (NT) and tumorigenic (T) tissues obtained from two Vav1–/–;Rasgrf2–/– mice. Scale bar, 1 cm. (C) Hematoxylin/eosin stained sections
of healthy and tumoral tissues obtained from a healthy wild type (upper panel) and a tumor–bearing Vav1–/–;Rasgrf2–/– (lower panel) mouse,
respectively. Scale bar, 100 mm. Asterisks, tumoral cells infiltrates in non–hematopoietic tissues.
doi:10.1371/journal.pone.0008229.g001
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Figure 2. Characterization of lymphoid tumors. (A) Cell suspensions from healthy and tumoral tissues obtained from mice of the indicated
genotypes (right) were stained with anti–CD3 antibodies and subjected to flow cytometry analysis. Red squares highlight CD3+ positive cell
populations present in the animals under study. The percentage of the CD3+ population in each case is indicated inside each panel. SSC, side scatter.
(B) Tissues from a tumor–bearing Vav1–/–;Rasgrf2–/– mouse (panels 3–7 counting from the left) were stained with either anti–CD3 (top panels) or anti–
PCNA (bottom panels) using immunohistochemistry techniques. As control, we stained thymus and spleen sections obtained from a wild type mouse
(first and second panel from left, respectively). Scale bar, 100 mm. (C) Cell suspensions were isolated from a healthy and three tumor–bearing
Vav1–/–;Rasgrf2–/– animals, stained with anti–CD4 and anti–CD8 antibodies, and analyzed by flow cytometry. (D) Cell suspensions derived from the
indicated tissues of a healthy and two tumoral Vav1–/–;Rasgrf2–/– mice were collected and blasts visualized by flow cytometry. In the y and x axes, the
SSC and FCS values range from 0 to 1,024, respectively. The vertical lines indicate the FCS point from where gated cells were considered as blasts.
FCS, forward scatter. The percentage of blasts in each case is indicated inside each panel. n = 5 and 10 for healthy and tumor–bearing animals,
respectively (panels A–D).
doi:10.1371/journal.pone.0008229.g002
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leukemia/lymphomas, this thymus–restricted tumorigenesis was
observed, although at lower rates, in one–year–old wild type
(<17%, n=25) and Rasgrf2–/– (<22%, n=20) mice (Figure 4D),
further suggesting that Vav1 accentuates the intrinsic tendency of
this mouse strain to develop thymic lymphomas rather than
promoting tumorigenesis in an autonomous fashion.
The Expression of RasGRF2 and Vav1 Is Altered in Very
Restricted Patients Subgroups Affected by
Hematopoietic Malignancies
The above observations indicated that the deletion of the Vav1
and/or Rasgrf2 gene could play a role in the development of
lymphoid tumors in humans. To get some insight into this
possibility, we first resorted to a quantitative reverse transcription
(RT)–PCR strategy to investigate the expression levels of both
transcripts in a commercial cDNA collection containing samples
from lymphocytes of healthy individuals and 42 independent
samples from patients affected by lymphoma/leukemia. Those
samples included several stages of lymphoma progression as well as
a number of B–cell– and T–cell–derived tumors. We did not find
any clear reduction in the VAV1 mRNA levels in human
lymphoma samples when compared with those present in
lymphocytes from healthy individuals (Figure 5, upper panel).
On the contrary, we recorded a 30% of cases in which VAV1
mRNA levels were at least 2–fold higher than those found in
normal lymphocytes. Instead, we detected a reduction in
RASGRF2 transcript levels in 81% of all the human lymphoma
cases analyzed (Figure 5, lower panel). Total elimination of the
mRNAs for this protein was observed in a small lymphocytic
lymphoma (stage I, sample 28), a peripheral T–cell lymphoma
(stage II, sample 38), and a diffuse large B–cell lymphoma (stage
IIE, sample 42) (Figure 5, lower panel). No statistically significant
upregulated levels of the RASGRF2 mRNA were observed in these
samples (Figure 5, lower panel). Since the number of samples
available for the RT–PCR experiment was rather limited, we
decided to expand these studies using in silico screenings with the
microarray data present in the Oncomine site (www.oncomine.
org). To this end, we first used a standard bioinformatics
comparison tool available in that database to investigate whether
the expression of VAV1 and/or RASGRF2 genes was deregulated in
hematopoietic tumor cells relative to their normal cell counter-
parts. Since few data are available on T–cell lymphomas, we used
microarray data derived from studies conducted on leukemia,
lymphoma and myeloma samples (see Materials and Methods).
These analyses indicated that VAV1 mRNA was overexpressed in
chronic lymphocytic leukemia, diffuse large B–cell lymphoma and
smoldering myeloma relative to control cells (Table 1). Instead,
reduced levels of this transcript were observed in another chronic
lymphocytic leukemia cohort and in hairy cell leukemia (Table 1).
In contrast to the RT–PCR data, we found no significant
variations in the expression levels of the RASGRF2 mRNA in the
microarray data available at the Oncomine site, indicating that
this gene is not commonly deregulated at least in the case of the
hematopoietic tumors selected in this study. We next analyzed
whether the expression levels of VAV1 and RASGRF2 genes were
significantly altered in specific subgroups of patients affected of
leukemia, lymphoma or myeloma. To this end, we used the cancer
outlier profile analysis (COPA) method available at the Oncomine
database (see Materials and Methods). This analysis allows the
identification of small fraction of samples showing statistically
significant variations in gene expression from the rest of the
Figure 3. The Rasgrf2 gene deficiency does not affect the normal development of T–cells (A) or mature lymphocyte (B) cell numbers.
Bar graphs show the mean percentages of thymocyte (upper panels) and splenic lymphocyte (lower panels) subpopulations derived from animals of
the indicated genotypes. Error bars represent the standard deviation (n = 5). *, P,0.01 compared to values obtained with wild type controls.
doi:10.1371/journal.pone.0008229.g003
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population patient cohort, thus bypassing the usual problem of the
intrinsic heterogeneity present in all analyses based on clinically–
derived tumors [23]. In the case of the VAV1 mRNA, we found a
significant downmodulation in a small subgroup of samples
derived from patients affected by diffuse large B–cell lymphoma
(Figure 6A, Table 2), chronic lymphocytic leukemia (Table 2),
and acute myeloid leukemia (Table 2). Instead, we could not
detect any patient tumor subgroup showing upregulation of VAV1
relative to the total patient cohort. In the case of RASGRF2, we
found groups of patients showing downmodulation of that gene in
acute lymphoblastic leukemia (Figure 6B, Table 3). Upregula-
tion was found in some cases of diffuse large B–cell lymphoma,
acute myeloid leukemia and chronic myelogenous leukemia
(Table 3). These results suggest that the changes in the expression
profile of VAV1 and RASGRF2 genes are not a general event
associated to the progression of hematopoietic tumors. Instead,
such variation appears to be concentrated on small, although
statistically significant patient subgroups.
Discussion
We have shown in this report that the double Vav1/Rasgrf2 gene
deficiency favors the development and progression of lymphoblas-
tic lymphoma–like tumors in mice. These tumors could be
classified in two different subsets in function of their level of
dissemination within the affected animal. A first subset was
characterized by its exclusive intrathymic localization. The second
subset showed that localization and, in addition, massive
infiltrations in extra–thymic hematopoietic–tissues and non–
hematopoietic tissues. This latter tumor subset was more
aggressive in nature, leading to elevated mortality rates in the
affected mice. Notwithstanding these differences in localization
and lethality, we observed that these two tumor subsets shared
many common biological features, including the expression of
CD3 molecules, the heteroclite expression of CD4 and CD8
surface markers, the upregulation of proteins generally involved in
proliferation (PCNA) and the lack of expression of TCR–induced
Figure 4. The lymphomas found in Vav1–/–;Rasgrf2–/– and Vav1–/– derive from the thymus. (A) Hematoxylin/eosin, anti–CD3 and anti–PCNA
staining of tissue sections obtained from a Vav1–/–;Rasgrf2–/– mouse with a thymus–localized lymphoma (panels 3–7 counting from left). As control,
we stained thymus and spleen sections obtained from a wild type mouse (first and second panel from left, respectively). Scale bar, 100 mm. (B) Cell
suspensions were obtained from a healthy Vav1–/–;Rasgrf2–/– (top) and a Vav1–/–;Rasgrf2–/– mouse with a thymus–localized tumor (bottom), stained
with anti–CD3 antibodies and analyzed by flow cytometry. The red square highlights the abnormal, CD3+ positive cell population found in the
thymus–localized tumor. The percentage of CD3+ cells in each case is indicated inside each panel. (C) Cell suspensions were obtained from a
Vav1–/–;Rasgrf2+/+ (top) and a Vav1–/–;Rasgrf2–/– (bottom) mouse containing thymus–localized tumors, stained with anti–CD4 and anti–CD8 antibodies
and analyzed by flow cytometry. Results similar to those shown in panels A–C were observed in 5 independent determinations. (D) Graph showing
the percentage of one–year old mice of the indicated genotypes with thymus–localized tumors.
doi:10.1371/journal.pone.0008229.g004
Vav1 and Rasgrf2 in Tumors
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8229
markers (i.e., CD69). It is likely therefore that these two
pathological subsets correspond to two different stages in
lymphoma progression. For the sake of simplicity, we will refer
to these two populations hereafter as ‘‘thymus–localized’’ and
‘‘widespread’’ lymphomas.
The Vav1 and Rasgrf2 gene deficiencies seem to contribute
differently to these two lymphoma stages. Thus, the loss of the Vav1
proto–oncogene increases preferentially the frequency of ‘‘thymus–
localized’’ lymphomas in one–year–old animals and, to a much lower
extent, the percentage of ‘‘widespread’’ tumors. This phenotype is
specifically driven by the deficiency in this Vav family member,
because we have not observed statistically significant increases in
deaths/tumor rates in Vav2–/–, Vav3–/– or Vav2–/–;Vav3–/– mice when
compared to control littermates. The single Rasgrf2 deficiency has
only minor or no effects per se in promoting the widespread and
thymus–localized subset of tumors, respectively. However, when
combined with the inactivation of the Vav1 gene, the Rasgrf2 gene
deficiency promotes a two–fold increase in the development of
‘‘widespread’’ lymphomas, shorter latency periods for the develop-
ment of the disease, and enhanced mortality/sickness rates. These
results suggest that the influence of the Rasgrf2 gene loss on
lymphomagenesis is totally contingent on the prior disruption of
Vav1 function in the T–cell compartment. Despite the above data, it
is worth noting that the tumoral phenotype described here requires
long latency periods to develop, is not fully penetrant, and is similar
anatomopathologically and immunophenotypically to the lympho-
mas spontaneously arising in wild type animals. These observations
indicate that the Vav1 and Rasgrf2 gene deficiencies do not trigger
single–handedly transformation but, rather, may offer an extra
selective advantage for the tumorigenic events that trigger the
fortuitous development of lymphomas in the B10.BR mouse strain
used in this study.
What is the basis of this enhanced tumorigenesis? In the case of
Vav1, the results reported here are totally at odds with the known
functions of this protein in cell signaling, proliferation and
oncogenesis [24]. Furthermore, Vav1 is also important in the T–
cell compartment for the assembly of optimal signaling responses
directly or indirectly related to cell growth, such as specific T–cell
developmental transitions, thymocyte selection steps, and prolifer-
ative responses to antigens in the case of mature T–lymphocytes
[25]. Such functions rely on the activation of Rac1, the Ras route
and, in some cases, catalytically–independent functions [25,26].
Given the implication of Vav1 in positive and negative TCR
selection events in thymocytes, it could be speculated that the
perturbation of thymic development or, alternatively, the lack of
elimination of immature T–cells carrying tumorigenic rearrange-
ments of antigen receptors in Vav1–/– mice could create a pool of
tumorigenic events that may eventually increase lymphoma
development rates in those animals. We do not support such
possibility, since we are not aware of any report indicating that
mouse strains with defective selection defects in the thymus are
prone to tumorigenesis in the T–cell compartment. On the other
hand, it could be also argued that the deficient signaling derived
from the Vav1 deficiency will favor other signaling routes in specific
Figure 5. Human RASGRF2 transcript levels are downregulated in some malignant hemopaties when compared to normal
lymphocytes. Left panels, cDNA samples from six control lymphocyte samples were subjected to quantitative RT–PCR analysis to observe the
variations in basal expression levels of VAV1 (top panel) and RASGRF2 (bottom panel) genes and to obtain the average expression values for each
gene (which were given an arbitrary value of 1) to be used as reference in the subsequent RT–PCR experiments with tumor samples. Right panels,
expression levels of VAV1 (top panel) and RASGRF2 (lower panel) mRNAs in lymphoma/leukemias (samples 7–48) of the indicated clinical stages by
RT–PCR. The horizontal lane represents the mean value of the control samples. P values in this figure were estimated by comparing the groups of
healthy and tumor samples. a.u., arbitrary units.
doi:10.1371/journal.pone.0008229.g005
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thymocyte subsets or, alternatively, place an additional pressure on
pre–neoplasic Vav–/– thymocytes that could create a Darwinian field
to promote the selection of highly mitogenic thymocytes carrying
pro–tumorigenic mutations in other signal transduction elements.
In this context, it is worth mentioning that Tybulewicz’s group has
shown recently that deficiencies in either Rac or Vav family genes
may favor the survival of TCRb– thymocytes due to hyperactivation
of the Notch signaling pathway [27], a route usually deregulated in
human lymphoblastic leukemia [28]. Cantrell’s group has also
shown that the elimination in thymocytes of RhoA function, a
GTPase activated by Vav family proteins, leads to a lymphoblastic
lymphoma very similar to the disseminated tumors found in Vav1–/–
and Vav1–/–;Rasgrf2–/– mice [29]. These data suggest that the role of
Vav1 in thymic lymphomagenesis could be linked to dysfunctions in
its direct downstream targets Rac1 and/or RhoA.
RasGRF2 promotes, similarly to Vav1, positive responses in
mature T–cells [18]. However, unlike the case of Vav1, there is
evidence indicating that it may also exert some tumor–suppressor
activities. Thus, several reports have shown decreased expression
and/or increased methylation of the Rasgrf2 gene in cancer cell
Figure 6. Examples of patient subgroups showing reduced expression levels of VAV1 (A) and RASGRF2 (B) genes. Graphs show the
variation in expression of those genes in samples obtained from patients in non–characterized tumors (NC) (A), B–cell non–Hodgkin’s lymphoma
(BNHL) (A), chronic lymphocytic leukemia (CLL) (B), diffuse large B–cell lymphoma (DBL) (A), B–cell acute lymphoblastic leukemia (B, upper panel)
and acute lymphoblastic leukemia (B, lower panel). Outlier groups were identified as indicated in Materials and Methods. The respective CODA scores
of each hit are indicated within each panel. The percentile of tumors showing the significant outlier values for the indicated gene is indicated on the
right. See Tables 2 and 3 for further details. a.u., arbitrary units.
doi:10.1371/journal.pone.0008229.g006
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lines and primary tumors [12-15]. Moreover, it has been
demonstrated that the overexpression of RasGRF2 negatively
affects the transforming properties of a colon cancer cell line [15].
Despite these observations, we do not consider that the putative
tumor suppressor activity of RasGRF2 is a plausible explanation
for the results reported here, because the Rasgrf2 deficiency only
contributes to tumorigenesis when combined with the Vav1
proto–oncogene loss. It is possible therefore that this coopera-
tivity in lymphomagenesis promotion is just another reflection of
the synergistic interactions occurring between the Vav1– and the
RasGRF2–dependent pathways in normal T–cells. Hence, and
similarly to the observations reported here, we have observed
before that the endogenous RasGRF2 plays important, but
subsidiary roles to the Vav1 route, in T–cell signaling. For
example, the Rasgrf2 gene deficiency does not affect the
proliferation and blast formation of TCR–stimulated T–lym-
phocytes but, instead, it aggravates the already defective
proliferative responses of Vav1–deficient T–cells to TCR–
dependent signals [18]. Since the lack of CD69 expression in
the Vav1–/–;Rasgrf2–/– tumor cells suggests that their growth is
mediated by TCR–independent mechanisms, the synergistic
interaction between the Vav1 and Rasgrf2 gene deficiencies will
probably need the alteration of TCR–independent routes rather
than the canonical TCR downstream pathways for this
hypothesis to be correct. The discrimination of all these
regulatory possibilities will have wait to the identification of the
signaling deficiency promoting the tumorigenesis in Vav1–
deficient lymphocytes.
The observation that Vav1 and Rasgrf2 gene deficiencies
promote enhanced tumorigenic rates in mice led us to verify
whether the expression of these genes could be deregulated in
human hematological tumors. Unfortunately, there are no many
data available on T–cell lymphomas/leukemias, so we could not
directly address changes in the expression of these two genes in
these cancer subtypes. In order to get a general view of the
expression of these two genes in hematological tumors, we have
carried out expression studies by quantitative RT–PCR in a
limited collection of hematopoietic tumors and, in addition, by in
silico profiling using microarray data publicly available at the
Oncomine database. The take home message of these studies is
that the human VAV1 and RASGRF2 genes do not show a
consistent and generalizable change pattern in hematopoietic
tumors such as lymphomas, leukemias or myelomas. However, we
did find small patient subgroups affected by some of those
pathologies that show statistically significant upregulation/down-
modulations of these two transcripts. Interestingly, we did not
detect a coincidence in the change patterns of those two genes in
the tumors analyzed so, if they contribute to the tumorigenesis,
they must do so in cooperation with other mutations. It will be
really important in the future to obtain a large group of T–cell
lymphoma/leukemia samples in order to assess the specific
implication of Vav1 and RasGRF2 in this tumorigenic context.
Not withstanding the actual role of these two proteins in T–cell
lymphomas/leukemias, our observations do have some interest
from a therapeutical point of view. Thus, it has been always
assumed that the inactivation of the function of Vav and Rho/Rac
family proteins could be of interest to treat cancer cells. The interest
on this possibility has been also fueled by observations indicating
that Vav and Rho/Rac family members are overexpressed in
certain types of human tumors [2,30-35]. However, our present
data puts a note of caution on those possible avenues, since they
indicate that the blockage of Vav family–dependent signaling could
Table 1. Variation in the expression levels of the VAV1 mRNA between normal and tumor cells.
Type of Regulation Type of Tumor and Normal Cell Gene Rank (top %) P value Reference
Upregulation Chronic lymphocytic leukemia vs B–cells, CD4+ T–cells, germinal
center B–cells memory B–lymphocyte and umbilical cord B– and T–cells
3 2.6610–6 [39]
Chronic lymphocytic leukemia vs B–lymphocytes 9 6.5610–4 [40]
Diffuse large B–cell lymphoma vs
B–cells, CD4+ T–cells, germinal center B–cells, memory B–lymphocyte and
umbilical cord B– and T–cells
8 6.8610–4 [39]
Smoldering myeloma vs bone marrow cells 5 2.8610–6 [41]
Downregulation Chronic lymphocytic leukemia vs B–cells, centroblasts, memory B–cells,
naı¨ve pregerminal center B–cells and small cleaved follicle center cells
3 1.4610–9 [42]
Hairy cell leukemia vs B–cells, centroblasts, memory B–cells, naı¨ve
pregerminalcenter B–cells and small cleaved follicle center cells
9 2.4610–6 [42]
*Searches were done using the following Oncomine parameters: gene: VAV1 or RASGRF2; analysis type: cancer vs normal analysis; dataset sizes: microarray data with a
minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value#0.001.
doi:10.1371/journal.pone.0008229.t001
Table 2. Outlier analysis of the expression of the VAV1 mRNA in hematopoietic tumors.
Type of Regulation Tumor type Gene Rank (top %) COPA value Percentile (%) Reference
Downregulation Diffuse large B–cell lymphoma 8 –3.210 5 [43]
Chronic lymphocytic leukemia 8 –5.073 5 [40]
Acute myeloid leukemia 4 –3.539 5 [44]
*Searches were done using the following Oncomine parameters: gene: VAV1; analysis type: outlier analysis; cancer type: leukemia, lymphoma and myeloma; dataset
sizes: microarray data with a minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value#1610–4; COPA value: less than –3.
doi:10.1371/journal.pone.0008229.t002
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be highly counterproductive in the case of lymphoblastic lymphoma
patients with reduced levels of RASGRF2 gene expression in tumor
cells. Hence, it will be important in the future to evaluate the
beneficial/adverse effect of Vav family–directed therapeutics in
different tumor types before initiating the search for Vav–specific
drugs and clinical trials with human patients.
Materials and Methods
Mouse Strains
Vav1–/–, Rasgrf2–/–, Vav1–/–;Rasgrf2–/–, Vav2–/–, Vav3–/– and
Vav2–/–;Vav3–/– mice have been previously described [18,36-38].
All mice used in these experiments were bred and maintained in
the SPF Animal Facility of the University of Salamanca using 12–
hour light/darkcycles. All animal–based experiments were ap-
proved by the Animal Use and Welfare Committees of the CSIC
and University of Salamanca as well as by the Bioethics Comittee
of the University of Salamanca. These approvals include review of
the experimental protocols to be used in the animal work and, in
addition, a description of the measures taken to avoid animal
discomfort or pain.
Histological and Immunohistochemical Analyses
Selected tissues were fixed in a buffered 4% formaldehyde
solution for 48 h and paraffin–embedded. Sections were cut,
stained with either hematoxylin/eosin (Sigma) and processed for
immunohistochemistry using antibodies to mouse CD3 (clone
F7.2.38, 1:200 dilution, Dako) and PCNA (clone PC10, 1:100
dilution, Cell Signaling). Immunoreactive signals were developed
using horseradish peroxidase–conjugated secondary antibodies to
mouse immunoglobulins (GE Healthcare).
Flow Cytometry Analysis
Single cell suspensions were prepared by homogenization of
tissues with the aid of 50 mm filters (Falcon). In the case of bone
marrow cells, phosphate–buffered saline solution was flushed
gently into the medullar cavity of isolated femoral bones and
resulting cell suspensions washed using cycles of low–speed
centrifugation and resuspension in phosphate–buffered saline
solution. After erythrocyte lysis using 0.17 M NH4Cl, lymphocytes
were stained with appropriate combinations of fluorescein–labeled
anti–CD4, phycoerythrin–labeled anti–CD3, and allophycocya-
nin–labeled anti–CD8 antibodies. For the determination of thymic
populations and splenic lymphocytes, cell suspensions were stained
with antibodies to surface markers using appropriate combinations
of fluorescein–labeled anti–CD4 and anti–CD44 antibodies,
peridinin chlorophyll protein–labeled anti–CD4, anti–CD25 and
anti–CD69 antibodies and allophycocyanin–labeled anti–CD4,
anti–CD8 and anti–B220 antibodies. All the antibodies were
obtained from BD Biosciences. Flow cytometry analyses were
conducted using a FACSCalibur system (BD Biosciences) and
analyzed using the Cell Quest (BD Biosciences), BD Paint–a–Gate
(BD Biosciences), and WinMDI 2.8 softwares [18].
Quantitative RT–PCR Analysis
A panel of cDNA samples obtained from normal and tumoral
lymphoid samples (TissueScan Lymphoma Tissue qPCR Array I
(2), Cat. Number LYRT101, Origene Technologies) was used to
analyze the expression of VAV1 and RASGRF2 transcripts in
different subsets of lymphomas. A detailed description of the
lymphoma samples contained in that array can be obtained in the
web of the commercial supplier (http://www.origene.com/
geneexpression/disease-panels/products/LYRT101. aspx). Quan-
titative PCR reactions were performed in the IQ5 Real–Time
PCR detection system (BioRad) using the SYBRH GreenTM two–
step qRT–PCR kit (Invitrogen). Sequences of the primers used for
the amplification of the human VAV1, RASGRF2 and GAPDH are
available upon request. As comparative control, we used the
average of the expression of those genes in six independent wild
type lymphoid tissues (which was given an arbitrary value of 1).
The expression values obtained in each experimental sample were
also normalized taking into consideration the expression levels of
the GAPDH gene. Quantitative PCR analyses were performed in
three independent replicas that yielded similar results.
In Silico Analysis of the Expression of VAV1 and RASGRF
Family Members in Hematological Tumors
To carry out the comparative analysis between normal and
tumor cells, we used the ‘‘differential cancer versus normal analysis’’
tool available at the Oncomine database (www.oncomine.org). The
settings used for the searches were: gene: VAV1 or RASGRF2; dataset
size: microarray data containing a minimum of 75 independent
samples; microarray platform: unrestricted; gene rank: top 10%; P
value#0.001. CODA analysis were done using the ‘‘outlier
analysis’’ tool present in the Oncomine database. The settings for
the searches were: gene: VAV1 or RASGRF2; cancer type: leukemia,
lymphoma and myeloma; dataset size: microarray data containing a
minimum of 75 independent samples; microarray platform:
unrestricted; gene rank: top 10%; P value#1610–4; COPA value:
less than –3 or more than 3 for the downregulated and upregulated
outliers, respectively.
Statistical Analysis
We used the logrank/Mantel–Cox test for Figure 1A, the
CODA algorithm for Figure 6 and Tables 2–3 and the
Student’s t–test for the rest of analyses.
Table 3. Outlier analysis of the expression of the RASGRF2 mRNA in hematopoietic tumors.
Type of Regulation Tumor type Gene Rank (top %) COPA value Percentile (%) Reference
Upregulation Diffuse large B–cell lymphoma 10 3.169 5 [45]
Acute myeloid leukemia 5 3.697 10 [46]
Chronic lymphocytic leukemia 9 3.612 10 [47]
Downregulation Acute lymphoblastic leukemia 3 –6.534 5 [48]
B–cell acute lymphoblastic leukemia 10 –3.997 10 [49]
*Searches were done using the following Oncomine parameters: gene: VAV1; analysis type: outlier analysis; cancer type: leukemia, lymphoma and myeloma; dataset
sizes: microarray data with a minimum of 75 independent samples; microarray platform: non restricted; gene rank, top 10%; P value#1610–4; COPA value: less than –3
for downregulated genes and higher than 3 for upregulated genes.
doi:10.1371/journal.pone.0008229.t003
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